Shree Ganesh Biotech India Ltd
Incorporated in 1982, Shree Ganesh Biotech Ltd is engaged in the trading of seeds and bhushi.[1]
- Market Cap ₹ 18.7 Cr.
- Current Price ₹ 0.47
- High / Low ₹ 0.79 / 0.46
- Stock P/E
- Book Value ₹ 1.60
- Dividend Yield 0.00 %
- ROCE 1.31 %
- ROE 0.96 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.29 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -22.0% over past five years.
- Company has a low return on equity of 0.84% over last 3 years.
- Working capital days have increased from 260 days to 861 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.68 | 2.12 | 8.54 | 7.86 | 5.87 | 2.47 | 17.21 | 72.64 | 62.45 | 20.28 | 22.96 | 4.97 | 5.02 | |
| 1.17 | 1.47 | 4.78 | 4.36 | 4.08 | 2.23 | 16.50 | 69.19 | 60.30 | 20.48 | 23.92 | 5.61 | 6.79 | |
| Operating Profit | 0.51 | 0.65 | 3.76 | 3.50 | 1.79 | 0.24 | 0.71 | 3.45 | 2.15 | -0.20 | -0.96 | -0.64 | -1.77 |
| OPM % | 30.36% | 30.66% | 44.03% | 44.53% | 30.49% | 9.72% | 4.13% | 4.75% | 3.44% | -0.99% | -4.18% | -12.88% | -35.26% |
| 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.28 | 0.05 | 0.56 | 1.06 | 1.35 | 1.15 | 1.38 | |
| Interest | 0.07 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.10 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.34 | 0.55 | 3.73 | 3.50 | 1.79 | 0.24 | 0.43 | 3.50 | 2.71 | 0.86 | 0.39 | 0.51 | -0.39 |
| Tax % | 0.00% | 1.82% | 0.00% | 0.00% | 0.00% | 0.00% | 25.58% | 27.71% | 25.09% | 26.74% | 28.21% | 27.45% | |
| 0.34 | 0.54 | 3.73 | 3.50 | 1.79 | 0.24 | 0.32 | 2.53 | 2.04 | 0.62 | 0.28 | 0.38 | -0.39 | |
| EPS in Rs | 0.09 | 0.15 | 1.01 | 0.95 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 | 0.01 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -22% |
| 3 Years: | -57% |
| TTM: | -76% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 3% |
| 3 Years: | -33% |
| TTM: | -183% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -42% |
| 3 Years: | -20% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.83 | 1.83 | 1.83 | 1.83 | 19.93 | 19.93 | 19.93 | 19.93 | 39.86 | 39.86 | 39.86 | 39.86 |
| Reserves | 2.41 | 2.94 | 17.54 | 21.04 | 37.31 | 37.54 | 37.86 | 40.39 | 22.49 | 23.12 | 23.39 | 23.77 |
| 0.61 | 0.50 | 0.06 | 0.19 | 0.19 | 0.19 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.12 | 0.03 | 0.01 | 3.30 | 6.66 | 7.06 | 16.64 | 33.24 | 17.18 | 10.64 | 0.24 | 0.17 | |
| Total Liabilities | 4.97 | 5.30 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.80 |
| 2.40 | 2.32 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.21 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 3.06 | 3.22 | 0.00 | 0.00 | 9.15 | 9.15 |
| 2.36 | 2.77 | 19.44 | 26.36 | 64.08 | 64.72 | 71.56 | 90.34 | 79.53 | 73.62 | 54.34 | 54.65 | |
| Total Assets | 4.97 | 5.30 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 63.80 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | -0.04 | -12.94 | 2.23 | -0.50 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.20 | |
| -0.11 | 0.00 | 2.53 | -2.36 | -32.07 | 0.99 | -2.36 | -3.37 | -10.09 | -10.21 | 9.80 | 8.19 | |
| 0.28 | -0.11 | 10.42 | 0.13 | 32.58 | 0.00 | 0.00 | -0.19 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.10 | -0.16 | 0.02 | 0.00 | 0.01 | -0.02 | 0.01 | 0.01 | 0.44 | -0.05 | -0.41 | 0.00 |
| Free Cash Flow | -0.07 | -0.04 | -10.62 | 2.23 | -0.51 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | -8.20 |
| CFO/OP | -14% | -6% | -344% | 64% | -28% | -421% | 348% | 132% | 522% | -5,080% | 1,052% | 1,259% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 260.71 | 456.25 | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 0.00 | 0.00 |
| Inventory Days | 483.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.59 | 846.14 |
| Days Payable | 46.27 | 0.00 | 0.00 | |||||||||
| Cash Conversion Cycle | 697.69 | 456.25 | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 46.59 | 846.14 |
| Working Capital Days | 310.68 | 380.50 | 383.81 | 475.99 | 779.12 | 2,036.32 | 249.20 | 53.71 | 12.80 | -132.11 | 50.08 | 860.72 |
| ROCE % | 9.04% | 12.25% | 30.45% | 16.47% | 4.45% | 0.42% | 1.23% | 5.92% | 4.42% | 1.37% | 0.76% | 1.31% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of permanent employees on the rolls employees |
|
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Reg. 34 (1) Annual Report.
- Submitted FY2025-26 annual report; 16th AGM on 28 September 2026.
- Intimation Of Book Closure Pursuant To Regulation 42 Of The SEBI (LODR) Regulations, 2015.
-
Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
- 16th AGM on 28 September 2026; financial statements adoption and Aman Patel reappointment.
-
Updation In The Website Of The Company
- Company updated its website to www.shreeganeshbiotech.bar and requested exchange record changes.
-
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
- Company reported no unutilized proceeds as of 30 June 2026; no Annexure-A required.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2]
SGBL is engaged in the business of production,
processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc. The
company provides crop solutions to the farmer
by supplying high yielding hybrid seeds and crop management namely micro nutrients, bio
products etc.